A comprehensive review on biomarkers associated with painful temporomandibular disorders

Abstract

Pain of the orofacial region is the primary complaint for which patients seek treatment. Of all the orofacial pain conditions, one condition that possess a significant global health problem is temporomandibular disorder (TMD). Patients with TMD typically frequently complaints of pain as a symptom. TMD can occur due to complex interplay between peripheral and central sensitization, endogenous modulatory pathways, and cortical processing. For diagnosis of TMD pain a descriptive history, clinical assessment, and imaging is needed. However, due to the complex nature of pain an additional step is needed to render a definitive TMD diagnosis. In this review we explicate the role of different biomarkers involved in painful TMD. In painful TMD conditions, the role of biomarkers is still elusive. We believe that the identification of biomarkers associated with painful TMD may stimulate researchers and clinician to understand the mechanism underlying the pathogenesis of TMD and help them in developing newer methods for the diagnosis and management of TMD. Therefore, to understand the potential relationship of biomarkers, and painful TMD we categorize the biomarkers as molecular biomarkers, neuroimaging biomarkers and sensory biomarkers. In addition, we will briefly discuss pain genetics and the role of potential microRNA (miRNA) involved in TMD pain.

References

[1] Macfarlane TV, . Oro-facial pain in the community: prevalence and associated impact. Community Dent. Oral. Epidemiol., 2000, 30: 52-60.

[2] Statistics. National Health and Nutrition Examination Survey Data. Centers for Disease Control and Prevention. National Center for Health. http://www.cdc.gov/nchs/nhanes.htm (2015).

[3] Lövgren A, . Temporomandibular pain and jaw dysfunction at different ages covering the lifespan a population-based study. Eur. J. Pain., 2016, 20: 532-540.

[4] Macfarlane TV, . Can one predict the likely specific orofacial pain syndrome from a self-completed questionnaire. Pain, 2004, 111: 270-277.

[5] Svensson P, Kumar A. Assessment of Risk factor for the orofacial pain and recent developments in classification implications for management. J. Oral. Rehab, 2016, 43: 977-989.

[6] Merskey, H. & Bugduk, N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms, ASP task force on taxonomy. 2nd ed. (IASP: Seattle; 1994).

[7] Schiffman E, . Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD. Consortium Network and Orofacial Pain Special Interest Group. J. Oral. Facial Pain. Headache, 2014, 28: 6-27.

[8] Murphy MK, MacBarb RF, Wong ME, Athanasiou KA. Temporomandibular disorders: a review of etiology, clinical management, and tissue engineering strategies. Int J. Oral. Maxillofac. Implants, 2013, 28: e393-e414.

[9] Calixtre LB, Grüninger BLS, Chaves TC, Oliveira AB. Is there an association between anxiety/depression and temporomandibular disorders in college students?. J. Applied Oral. Sci., 2014, 22: 15-21.

[10] Pigg M, . New international classification of orofacial pain: what is in it for endodontists?. J. Endod., 2021, 47: 345-357.

[11] Chisnoiu AM, . Factors involved in the etiology of temporomandibular disorders - a literature review. Clujul Med., 2015, 88: 473-478.

[12] Roger BF, . Long-term changes in biopsychosocial characteristics related to temporomandibular disorder: findings from the OPPERA study. Pain, 2018, 159: 2403-2413.

[13] Dworkin SF, Massoth DL. Temporomandibular disorders and chronic pain: disease or illness?. J. Prosthet. Dent., 1994, 72: 29-38.

[14] Nardi R, . Co-morbidity does not reflect complexity in internal medicine patients. Eur. J. Intern Med, 2007, 18: 359-368.

[15] Aggarwal VR, . The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors?. Int. J. Epidemiol., 2006, 35: 468-476.

[16] Aiken A, Bouloux G, Hudgins P. MR imaging of the temporomandibular joint. Magn. Reson Imaging Clin. N. Am., 2012, 20: 397-412.

[17] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharm. Ther., 2001, 69: 89-95.

[18] FDA-NIH Biomarker Working Group. BEST (biomarkers, endpoints, and other tools) resource. Bethesda: Silver Spring Food Drug Adm (US) Co-published by Natl Institutes Heal (US), (2016).

[19] Van der Miesen MM, Lindquist MA, Wager TD. Neuroimaging-based biomarkers for pain: state of the field and current directions. Pain. Rep., 2019, 4: e751.

[20] Ceusters W, . Perspectives on next steps in classification of orofacial pain—Part 3: biomarkers of chronic orofacial pain—from research to clinic. J. Oral. Rehabil, 2015, 42: 956-966.

[21] Zwiri A, . Biomarkers for temporomandibular disorders: current status and future directions. Diagnostics (Basel)., 2020, 10: 303.

[22] Davis KD, . Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat. Rev. Neurol., 2020, 16: 381-400.

[23] Goulet, J. P. & Velly, A. M. (eds). Orofacial Pain Biomarkers (Springer, 2017).

[24] Kringel D, . A machine-learned analysis of human gene polymorphisms modulating persisting pain points to major roles of neuroimmune processes. Eur. J. Pain., 2018, 22: 1735-1756.

[25] Ernberg M. The role of molecular pain biomarkers in temporomandibular joint internal derangement. J. Oral. Rehabil., 2017, 44: 481-491.

[26] Doshi LT, . Biomarkers in temporomandibular disorder and trigeminal neuralgia: a conceptual framework for understanding chronic pain. Can. J. Pain., 2020, 4: 1-18.

[27] Yaman D, . Correlation of molecular biomarker concentrations between synovial fluid and saliva of the patients with temporomandibular disorders. Clin. Oral. Investig., 2020, 24: 4455-4461.

[28] Minyé HM. Neuroplasticity and central sensitization in orofacial pain and TMD. OBM Neurobio, 2020, 4: 11.

[29] Sorenson A, . Expression of interleukin-1 and temporomandibular disorder: contemporary review of the literature. Cranio, 2018, 36: 268-272.

[30] Bouloux GF. Temporomandibular joint pain and synovial fluid analysis: a review of the literature. J. Oral. Maxillofac. Surg., 2009, 67: 2497-2504.

[31] Alstergren P, Ernberg M, Kvarnström M, Kopp S. Interleukin-1beta in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility, and anterior open bite. J. Oral. Maxillofac. Surg., 1998, 56: 1059-1065.

[32] Alstergren P, Benavente C, Kopp S. Interleukin-1β, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J. Oral. Maxillofac. Surg., 2003, 61: 1171-1178.

[33] Ogura N, . MCP-1 production in temporomandibular joint inflammation. J. Dent. Res, 2010, 89: 1117-1122.

[34] Slade GD, . Painful temporomandibular disorder: decade of discovery from OPPERA studies. J. Dent. Res., 2016, 95: 1084-1092.

[35] de Alcântara Camejo F, . Interleukin-6 expression in disc derangement of human temporomandibular joint and association with osteoarthrosis. J. Craniomaxillofac Surg., 2017, 45: 768-774.

[36] Shinoda C, Takaku S. Oral and maxillofacial pathology: Interleukin-1 β, interleukin-6, and tissue inhibitor of metalloproteinase-1 in the synovial fluid of the temporomandibular joint with respect to cartilage destruction. Oral. Dis., 2008, 6: 383-390.

[37] Poluha RL, Grossmann E. Inflammatory mediators related to arthrogenic temporomandibular dysfunctions. Braz. J. Pain., 2018, 1: 60-65.

[38] Sato J, . Expression of interleukin 8 in synovial tissues in patients with internal derangement of the temporomandibular joint and its relationship with clinical variables. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod., 2007, 103: 467-474.

[39] Jounger SL, . Increased levels of intramuscular cytokines in patients with jaw muscle pain. J. Headache Pain., 2017, 18

[40] Slade G. D. et al. Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. Pain 152, 2802–2812 (2011).

[41] Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett., 2004, 361: 184-187.

[42] Alstergren, P. in Peripheral receptor targets for analgesia. (eds Cairns, B. E.), 419–454 (John Wiley & Sons, Inc, 2009).

[43] Guven O, Tekin U, Salmanoglu B, Kaymak E. Tumor necrosis factor-alpha levels in the synovial fluid of patients with temporomandibular joint internal derangement. J. Craniomaxillofac Surg., 2015, 43: 102-105.

[44] Nordahl S, Alstergren P, Kopp S. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J. Oral. Maxillofac. Surg., 2000, 58: 525-530.

[45] Fredriksson L, Alstergren P, Kopp S. Tumor necrosis factor-alpha in temporomandibular joint synovial fluid predicts treatment effects on pain by intraarticular glucocorticoid treatment. Mediators Inflamm., 2006, 2006: 59425.

[46] Puliti M, . Contribution of matrix metalloproteinase 2 to joint destruction in group B streptococcus-induced murine arthritis. Arthritis Rheumatol., 2012, 64: 1089-1097.

[47] Yoshida K, . Expression of matrix metalloproteinases and aggrecanase in the synovial fluids of patients with symptomatic temporomandibular disorders. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod., 2006, 102: 22-27.

[48] Tabeian H, . IL-1β damages fibrocartilage and upregulates MMP-13 expression in fibrochondrocytes in the condyle of the temporomandibular joint. Int J. Mol. Sci., 2019, 20: 2260.

[49] Gho WG, Choi Y, Park KH, Huh JK. Expression of collagenases (matrix metalloproteinase-1, 8, 13) and tissue inhibitor of metalloproteinase-1 of retrodiscal tissue in tem-poromandibular joint disorder patients. J. Korean Assoc. Oral. Maxillofac. Surg., 2018, 44: 120-127.

[50] Loreto C, . MMP-7 and MMP-9 are overexpressed in the synovial tissue from severe temporomandibular joint dysfunction. Eur. J. Histochem, 2020, 64: 3113.

[51] Srinivas R, . Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod., 2001, 91: 517-525.

[52] Kanyama M, . Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis. J. Orofac. Pain., 2000, 14: 20-30.

[53] Fujita H, . MMP-3 activation is a hallmark indicating an early change in TMJ disorders and is related to nitration. Int J. Oral. Maxillofac. Surg., 2009, 38: 70-78.

[54] Huang X, . Effect of psychological stress on the structure of the temporomandibular joint and the expression of MMP-3 and TIMP-3 in the cartilage in rats. Br. J. Oral. Maxillofac. Surg., 2014, 52: 709-714.

[55] Nascimento GC, Rizzi E, Gerlach RF, Leite-Panissi CR. Expression of MMP-2 and MMP-9 in the rat trigeminal ganglion during the development of temporomandibular joint inflammation. Braz. J. Med Biol. Res, 2013, 46: 956-967.

[56] Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M. Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod., 2002, 94: 328-332.

[57] Alstergren P, Kopp S. Prostaglandin E2 in temporomandibular joint synovial fluid and its relation to pain and inflammatory disorders. J. Oral. Maxillofac. Surg., 2000, 58: 180-188.

[58] Basi DL, . Human temporomandibular joint and myofascial pain biochemical profiles: a case-control study. J. Oral. Rehabil., 2012, 39: 326-337.

[59] Miller KE, Hoffman EM, Sutharshan M, Schechter R. Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms. Pharm. Ther., 2011, 130: 283-309.

[60] Lam DK, Sessle BJ, Cairns BE, Hu JW. Neural mechanisms of temporomandibular joint and masticatory muscle pain: a possible role for peripheral glutamate receptor mechanisms. Pain. Res. Manag., 2005, 10: 145-152.

[61] Alstergren P, . Glutamate-induced temporomandibular joint pain in healthy individuals is partially mediated by peripheral NMDA receptors. J. Orofac. Pain., 2010, 24: 172-180.

[62] Sommer C. Is serotonin hyperalgesic or analgesic?. Curr. Pain. Headache Rep., 2006, 10: 101-106.

[63] Ernberg, M. in Peripheral Receptor Targets for Analgesia (eds Cairns, B. E.), 243–274 (John Wiley & Sons, Inc, 2009).

[64] Ernberg M, . Pain allodynia and serum serotonin level in orofacial pain of muscular origin. J. Orofac. Pain., 1999, 13: 56-62.

[65] Kopp S. Influence of neuropeptides, serotonin and interleukin1 beta on temporomandibular joint pain and inflammation. J. Oral. Maxillofac. Surg., 1998, 56: 189-191.

[66] Ernberg M, . Plasma and serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J. Orofac. Pain., 2000, 14: 37-46.

[67] Kopp S, Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm., 2002, 11: 211-217.

[68] Fredriksson L, Alstergren P, Kopp S. Serotonergic mechanisms influence the response to glucocorticoid treatment in TMJ arthritis. Mediators Inflamm., 2005, 2005: 194-201.

[69] Dawson A, . Dopamine in plasma- a biomarker for myofascial TMD pain?. J. Headache Pain., 2016, 17

[70] Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat. Rev. Neurol., 2016, 12: 635-650.

[71] Sato J, . Relationship of calcitonin gene-related peptide in synovial tissues and temporomandibular joint pain in humans. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. En.-dod., 2004, 98: 533-540.

[72] Sisignano M, Lotsch J, Parnham JM, Geisslinger G. Potential biomarkers for persistent and neuropathic pain therapy. Pharm. Ther., 2019, 199: 16-29.

[73] Denk F, Bennet DL, Mc Mahon SB. Nerve growth factor and pain mechanism. Annu Rev. Neurosci., 2017, 40: 307-325.

[74] Chen W, . Elevated levels of nerve growth factor in the bladder syndrome-interstitial cystitis: a meta-analysis. Springerplus, 2016, 13

[75] Ke J, . Up-regulation of vascular endothelial growth factor in synovial fibroblasts from human temporomandibular joint by hypoxia. J. Oral. Pathol. Med, 2007, 36: 290-296.

[76] Andersen HH, Durouxb M, Gazerania P. MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions. Neurobiol. Dis., 2014, 71: 150-168.

[77] López-González MJ, Landry M, Favereaux A. MicroRNA and chronic pain: from mechanisms to therapeutic potential. Pharm. Ther., 2017, 180: 1-15.

[78] Xu J, . MicroRNA221–3p modulates Ets-1 expression in synovial fibroblasts from patients with osteoarthritis of temporomandibular joint. Osteoarthr. Cartil., 2016, 24: 2003-2011.

[79] Li W, . Potential novel prediction of TMJ-OA: MiR-140-5p regulates inflammation through Smad/TGF-β signaling. Front. Pharm., 2019, 10: 15.

[80] Mao, D. et al. MicroRNA‐101a‐3p could be involved in the pathogenesis of temporomandibular joint osteoarthritis by mediating UBE2D1 and FZD4. J. Oral Pathol. Med. 50, 236–243 (2020).

[81] Zhang A, . Knockout of miR-21-5p alleviates cartilage matrix degradation by targeting Gdf5 in temporomandibular joint osteoarthritis. Bone Jt. Res, 2020, 9: 689-700.

[82] Ohrbach R, Dworkin SF. Five-year outcomes in TMD: relationship of changes in pain to changes in physical and psychological variables. Pain, 1998, 74: 315-326.

[83] Yap AU, . Multiple pains and psychosocial functioning/psychologic distress in TMD patients. Int. J. Prosthodont., 2002, 15: 461-466.

[84] Sarlani E, Greenspan JD. Why look in the brain for answers to temporomandibular disorder pain?. Cells Tissues Organs, 2005, 180: 69-75 14.

[85] Fernandez-de-las-Penas C, . Bilateral widespread mechanical pain sensitivity in women with myofascial temporomandibular disorder: evidence of impairment in central nociceptive processing. J. Pain., 2009, 10: 1170-1178.

[86] Yin Y, . The neuro-pathophysiology of temporomandibular disorders-related pain: a systematic review of structural and functional MRI studies. J. Headache Pain., 2020, 21

[87] Wilcox SL, . Anatomical changes within the medullary dorsal horn in chronic temporomandibular disorder pain. Neuroimage, 2015, 117: 258-266.

[88] Moayedi M, . Contribution of chronic pain and neuroticism to abnormal forebrain gray matter in patients with temporomandibular disorder. Neuroimage, 2011, 55: 277-286.

[89] Gustin SM, . Different pain, different brain: thalamic anatomy in neuropathic and non-neuropathic chronic pain syndromes. J. Neurosci., 2011, 31: 5956-5964.

[90] Younger JW, . Chronic myofascial temporomandibular pain is associated with neural abnormalities in the trigeminal and limbic systems. Pain, 2010, 149: 222-228.

[91] Zhang J, . Spontaneous brain activity and connectivity in female patients with temporomandibular joint synovitis pain: a pilot functional magnetic resonance imaging study. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio., 2018, 126: 363-374.

[92] Ichesco E, . Altered functional connectivity between the insula and the cingulate cortex in patients with temporomandibular disorder: a pilot study. Headache, 2011, 52: 441-454.

[93] Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Ann. N. Y Acad. Sci., 2008, 1124: 1-38.

[94] Weissman-Fogel I, . Abnormal cortical activity in patients with temporomandibular disorder evoked by cognitive and emotional tasks. Pain, 2011, 152: 384-396.

[95] Kucyi A, . Enhanced medial prefrontal-default mode network functional connectivity in chronic pain and its association with pain rumination. J. Neurosci., 2014, 34: 3969-3975.

[96] Chen Q, Heinricher MM. Descending control mechanisms and chronic pain. Curr. Rheumatol. Rep., 2019, 21: 13.

[97] Costa, P. T., McCrae, R. R. Revised NEO personality (NEO-PI-R) and NEO five factor inventory (NEO-FFI) professional manual. Psychology Assessment Resources, Odessa, Florida (1992).

[98] He SS, . Spontaneous neural activity alterations in temporomandibular disorders: a cross-sectional and longitudinal resting-state functional magnetic resonance imaging study. Neuroscience, 2014, 278: 1-10.

[99] Salomons TV, . Perceived helplessness is associated with individual differences in the central motor output system. Eur. J. Neurosci., 2012, 35: 1481-1487 44.

[100] Sullivan MJL, Bishop SR, Pivik J. The pain Catastrophizing scale: development and validation. Psychol. Assess., 1995, 7: 524-532.

[101] Harfeldt K, . Spectroscopic differences in posterior insula in patients with chronic temporomandibular pain. Scand. J. Pain., 2018, 18: 351-361.

[102] Harris RE, . Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum., 2008, 58: 903-907.

[103] Harris RE, . Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum., 2009, 60: 3146-3152.

[104] Fayed N, . Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther., 2010, 12: R134.

[105] Feraco P, . Metabolic abnormalities in pain-processing regions of patients with fibromyalgia: a 3T MR spectroscopy study. AJNR Am. J. Neuroradiol., 2011, 32: 1585-1590.

[106] Gerstner, G. E. et al. Posterior insular molecular changes in myofascial pain. J. Dent. Res. 91, 485-490 (2012).

[107] Rolke R, . Quantitative sensory testing in the german research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain, 2006, 123: 231-243.

[108] Zhou P, . Quantitative sensory testing for assessment of somatosensory function in human oral mucosa: a review. Acta Odontologica Scandinavica, 2018, 76: 13-20.

[109] Cruz-Almeida YF, Fillingim RB. Can quantitative sensory testing move us closer to mechanism-based pain management?. Pain. Med., 2014, 15: 61-72.

[110] Yang G, . Somatosensory abnormalities in Chinese patients with painful temporomandibular disorders. J. Headache Pain., 2016, 17

[111] Kothari SF, Baad-Hansen L, Oono Y, Svensson P. Somatosensory assessment and conditioned pain modulation in temporomandibular disorders pain patients. Pain, 2015, 156: 2545-2555.

[112] Yang G, Baad-Hansen L, Wang K, Xie QF, Svensson P. A study on variability of quantitative sensory testing in healthy participants and painful temporomandibular disorder patients. Somatosens. Mot. Res, 2014, 31: 62-71.

[113] Greenspan JD, . Pain sensitivity and autonomic factors associated with development of TMD: The OPPERA prospective cohort study. J. Pain., 2013, 14: T63-T74.

[114] Carvalho GF, . Reduced thermal threshold in patients with temporomandibular dis-orders. J. Oral. Rehabil., 2016, 43: 401-408.

[115] Touche R, . Evidence for central sensitization in patients with temporomandibular disorders: a systematic review and meta-analysis of observational studies. Pain. Pract., 2018, 18: 388-409.

[116] Wang Y, . Assessment of somatosensory changes in Chinese temporomandibular disorders arthralgia patients by quantitative sensory testing. J. Oral. Rehabil., 2020, 47: 1129-1141.

[117] Diatchenko L, . Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet., 2005, 14: 135-143.

[118] Visscher CM, Lobbezoo F. TMD pain is partly heritable. a systematic review of family studies and genetic association studies. J. Oral. Rehabil., 2015, 42: 386-399.

[119] D’Agnelli S, . Fibromyalgia: genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers. Mol. Pain., 2019, 15

[120] Slade GD, Diatchenko L, Ohrbach R, Maixner W. Orthodontic treatment, genetic factors, and risk of temporomandibular disorder. Semin Orthod., 2008, 14: 146-156.

[121] Chen H, . Multisystem dysregulation in painful temporomandibular disorders. J. Pain., 2013, 14: 983-996.

[122] Demir CY, Ersoz ME. Biochemical changes associated with temporomandibular disorders. J. Int Med Res, 2019, 47: 765-771.

[123] Rodríguez de Sotillo D, Velly AM, Hadley M, Fricton JR. Evidence of oxidative stress in temporomandibular disorders: a pilot study. J. Oral. Rehabil., 2011, 38: 722-728.